Eli Lilly and Company
MET antibody drug conjugates

Last updated:

Abstract:

Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.

Status:
Grant
Type:

Utility

Filling date:

17 Nov 2017

Issue date:

9 Nov 2021